EUVIMEDEUVIMED entdecken
Validierungsstudie

Development and validation of a new prognostic tool for hepatocellular carcinoma undergoing resection: The Weighted Alpha-Fetoprotein Tumor Burden Score (WATS)

Tonghui Lu, Kailing Xie, Yan Chen, Mingxiu Ma, Yaming Guo, Tianqiang Jin, Chaoliu Dai, Feng Xu

European Journal of Surgical Oncology · 2025

DOI: 10.1016/j.ejso.2025.109677 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift European Journal of Surgical Oncology, 2025. Verfasst von Tonghui Lu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, 110004, People's Republic of China. Electronic address: 4694…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, alpha-Fetoproteins, Tumor Burden. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Natural Science Foundation of Liaoning Province, Department of Education of Liaoning Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: This study aimed to develop and validate a novel prognostic index, the Weighted Alpha-Fetoprotein Tumor Burden Score (WATS), for predicting outcomes in hepatocellular carcinoma (HCC) patients undergoing resection. MATERIALS AND METHODS: A total of 772 resected HCC patients were included. WATS was developed and validated using an 8:2 cohort split. The score was derived from multivariate Cox regression, resulting in the formula: WATS = 0.73 × tumor number +0.17 × tumor size +0.1 × ln AFP. The time-dependent ROC curve assessed the score's predictive ability, while restricted cubic splines evaluated the dose-response relationship between WATS and prognostic outcomes. Kaplan-Meier curves and multivariate Cox regression further validated the prognostic accuracy. RESULTS: In the training cohort, AUCs for progression-free survival (PFS) at 1, 2, 3, 4, and 5 years were 0.683, 0.664, 0.661, 0.633, and 0.620, respectively; for overall survival (OS), they were 0.757, 0.732, 0.703, 0.672, and 0.670, respectively. In the validation cohort, AUCs for PFS were 0.711, 0.654, 0.671, 0.662, and 0.684, respectively; for OS, they were 0.724, 0.688, 0.642, 0.698, and 0.721, respectively. WATS outperformed other complex indicators and staging systems. RCS analysis showed a linear relationship between WATS and outcomes. The nomogram based on WATS demonstrated excellent discrimination, calibration, and clinical benefit. CONCLUSION: WATS is a novel, reliable prognostic tool for HCC post-resection, offering enhanced patient stratification and risk assessment, thereby improving clinical management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver Neoplasmsalpha-FetoproteinsTumor BurdenHepatectomyHumansMaleFemaleMiddle AgedPrognosisAgedSurvival RateAdultROC Curve

Stichwörter der Autor:innen

Alpha-fetoproteinHepatocellular carcinomaPrognosisSurgical resectionTumor burden

Substanzen

alpha-Fetoproteins

Autor:innen und Institutionen

  • Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, 110004, People's Republic of China. Electronic address: 469417594@qq.com.
  • Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, 110004, People's Republic of China; Department of General Surgery, The Second Xiangya Hospital of Central South University, Changs…
  • Department of Cardiology, Second Hospital of Dalian Medical University, Dalian, People's Republic of China. Electronic address: 604780228@qq.com.
  • Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, 110004, People's Republic of China. Electronic address: 525904116@qq.com.
  • Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, 110004, People's Republic of China. Electronic address: 2793171608@qq.com.
  • Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, 110004, People's Republic of China. Electronic address: jtq19950827@163.com.

Förderung

  • Natural Science Foundation of Liaoning Province
  • Department of Education of Liaoning Province

Zitieren

APA

Lu, T., Xie, K., Chen, Y., Ma, M., Guo, Y., Jin, T., Dai, C., & Xu, F. (2025). Development and validation of a new prognostic tool for hepatocellular carcinoma undergoing resection: The Weighted Alpha-Fetoprotein Tumor Burden Score (WATS). European Journal of Surgical Oncology. https://doi.org/10.1016/j.ejso.2025.109677

Vancouver

Lu T, Xie K, Chen Y, Ma M, Guo Y, Jin T, et al. Development and validation of a new prognostic tool for hepatocellular carcinoma undergoing resection: The Weighted Alpha-Fetoprotein Tumor Burden Score (WATS). European Journal of Surgical Oncology. 2025. doi:10.1016/j.ejso.2025.109677

BibTeX
@article{Lu2025,
  author = {Lu, Tonghui and Xie, Kailing and Chen, Yan and Ma, Mingxiu and Guo, Yaming and Jin, Tianqiang and Dai, Chaoliu and Xu, Feng},
  title = {Development and validation of a new prognostic tool for hepatocellular carcinoma undergoing resection: The Weighted Alpha-Fetoprotein Tumor Burden Score (WATS)},
  journal = {European Journal of Surgical Oncology},
  year = {2025},
  doi = {10.1016/j.ejso.2025.109677}
}
Kostenlos starten →